Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Cash & Equivalents (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Cash & Equivalents for 16 consecutive years, with $145.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 60.17% to $145.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $145.3 million, a 60.17% decrease, with the full-year FY2024 number at $181.8 million, down 44.99% from a year prior.
  • Cash & Equivalents was $145.3 million for Q3 2025 at Usana Health Sciences, down from $151.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $364.9 million in Q3 2024 to a low of $145.3 million in Q3 2025.
  • A 5-year average of $262.2 million and a median of $261.2 million in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 32.83% in 2021, then crashed 60.17% in 2025.
  • Usana Health Sciences' Cash & Equivalents stood at $248.7 million in 2021, then increased by 15.97% to $288.4 million in 2022, then increased by 14.56% to $330.4 million in 2023, then crashed by 44.99% to $181.8 million in 2024, then decreased by 20.04% to $145.3 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Cash & Equivalents are $145.3 million (Q3 2025), $151.3 million (Q2 2025), and $179.6 million (Q1 2025).